GNCA - Genocea Biosciences: Updates To Thesis

Shares of Genocea Biosciences (GNCA) have gained around 40% since my May 2018 Reader Inquiry piece explored the company's pivot in focus from a late-stage immunotherapy candidate for the treatment of genital herpes to the lucrative yet crowded immuno-oncology arena. So far in 2019, shares are sporting a 360% gain after recovering from lows in January.

Recently, buying interest returned after the company's presentation of phase 1/2a data for neoantigen vaccine candidate GEN-009 was highlighted as a top 10 featured abstract at ASCO (American Society of Clinical Oncology) annual meeting. This reminded me